Over a billion people are affected by fungal infections every year, ranging in severity from topical skin conditions like athlete’s foot to life-threatening fungal blood infections.
The infection is more likely to occur when the body’s immune system is compromised due to an illness like HIV/AIDS, cancer or when receiving antibiotic treatment. There is a pressing need to develop efficient and disease-specific antifungal agents to mitigate this growing drug resistance problem. Traditional antifungal therapeutics need to get inside the cell to attack the infection but have trouble targeting and penetrating the fungi membrane wall. Also, since fungi are metabolically similar to mammalian cells, existing drugs can have trouble differentiating between healthy and infected cells. Recognizing this, IBM scientists applied an organic catalytic process to facilitate the transformation of PET (waste), into entirely new molecules that can be transformed into antifungal agents.
Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research -Almaden (IBM) have unveiled a nanomedicine breakthrough in common plastics like polyethylene terephthalate (PET) that can be converted into non-toxic and biocompatible materials designed to specifically target and attack fungal infections. This is significant as plastic bottles are typically recycled by mechanical grounding and can mostly be reused only in secondary products like clothes, carpeting or playground equipment.
These new antifungal agents self-assemble through a hydrogen-bonding process, sticking to each other like molecular Velcro in a polymer-like fashion to form nanofibers. This is important because these antifungal agents are only active as a therapeutic in the fiber or polymer-like form. This novel nanofiber carries a positive charge and can selectively target and attach to only the negatively-charged fungal membranes based on electrostatic interaction. It then breaks through and destroys the fungal cell membrane walls, preventing it from developing resistance.
According to Dr Yi Yan Yang, Group Leader, IBN, “The ability of these molecules to self-assemble into nanofibers is important because unlike discrete molecules, fibers increase the local concentration of cationic charges and compound mass. This facilitates the targeting of the fungal membrane and its subsequent lysis, enabling the fungi to be destroyed at low concentrations.” Leveraging IBM Research’s computational capabilities, the researchers simulated the antifungal assemblies, predicting which structural modifications would create the desired therapeutic efficacy. “As computational predictive methodologies continue to advance, we can begin to establish ground rules for self assembly to design complex therapeutics to fight infections as well as the effective encapsulation, transport and delivery of a wide variety of cargos to their targeted diseased sites,” said Dr. James Hedrick, Advanced Organic Materials Scientist, IBM Research. The minimum inhibitory concentration (MIC) of the nanofibers, which is the lowest concentration that inhibits the visible growth of fungi, demonstrated strong antifungal activity against multiple types of fungal infections. In further studies conducted by Singapore’s IBN, testing showed the nanofibers eradicated more than 99.9% of C. albicans, a fungal infection causing the third most common blood stream infection in the United States, after a single hour of incubation and indicated no resistance after 11 treatments. Conventional antifungal drugs were only able to suppress additional fungal growth while the infection exhibited drug resistance after six treatments.
Additional findings of this research indicated the nanofibers effectively dispersed fungal biofilms after one-time treatment while conventional antifungal drugs were not effective against biofilms. The in vivo antifungal activity of the nanofibers was also evaluated in a mouse model using a contact lens-associated C. albicans biofilm infection. The nanofibers significantly decreased the number of fungi, hindered new fungal structure growth in the cornea and reduced the severity of existing eye inflammation. These experiments also showed mammalian cells survived long after incubation with the nanofibers, indicating excellent in vitro biocompatibility. In addition, no significant tissue erosion is observed in the mouse cornea after topical application of the nanofibers.
In recent years, the number of opportunistic fungal infections has increased due to growing populations of patients with weakened immune systems, for example due to cancer, organ transplant or HIV/AIDS.
The Latest on: Antifungal agents
[google_news title=”” keyword=”Antifungal agents” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antifungal agents
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024on May 16, 2024 at 6:00 am
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery ...
- How to Get Mold Out of Carpeton May 15, 2024 at 2:53 pm
We may earn revenue from the products available on this page and participate in affiliate programs. Learn More › Mold is a living, growing organism that can appear as green, gray, or white patches on ...
- Keto Diet Boosts Effects of Antifungal Drug in Miceon May 9, 2024 at 4:59 pm
One thing is certain: The threat of fungal infections is growing, as fungi either evolve ways to evade drugs that once worked, or pop up in places they haven't been seen before. "We have limited ...
- Keto Diet Boosts Lifesaving Antifungal Drug in Miceon May 9, 2024 at 9:07 am
It’s possible that a keto diet influences the gut microbiome in a way that changes how the drug is absorbed. The dietary shift could also boost the immune system, making it easier for the drug to ...
- Antifungal agents articles from across Nature Portfolioon May 6, 2024 at 4:59 pm
Antifungal agents are substances that inhibit the spread of fungi by killing fungal cells or spores or preventing their growth. Echinocandins are antifungal drugs that inhibit hyphal growth and ...
- Researchers review current evidence on Candida auris, an emerging multidrug-resistant yeaston May 6, 2024 at 9:56 am
Different C. auris strains exhibit varied degrees of resistance to antifungal agents including azoles, amphotericin B, and echinocandins. According to current recommendations, echinocandin monotherapy ...
- Exeter announces new £3.4 million global funding for solutions to antifungal drug resistanceon May 3, 2024 at 7:50 am
Considering this threat, increasing frequencies of antifungal drug resistance amongst fungi in the natural environment and in patients undergoing hospital treatment means even fewer drugs are ...
- Top 8 Best Antifungal Supplements in 2024on April 29, 2024 at 5:00 pm
Look for supplements that contain natural antifungal agents such as caprylic acid, oregano oil, and garlic extract. These ingredients have been shown to be effective in fighting fungal infections.
- GSK revises Scynexis licensing deal for antifungal agenton January 2, 2024 at 3:59 pm
Scynexis (NASDAQ:SCYX) fell ~9% premarket Wednesday after disclosing that British drugmaker GSK (GSK) amended its license agreement for its antifungal drug Brexafemme (ibrexafungerp tablets).
- Fighting the rising tide of antifungal resistance: a global challengeon September 20, 2023 at 10:56 am
F2G is a biotech company that specializes in developing therapies to treat invasive fungal infections through a novel class of antifungal agents called the orotomides. There are at least 5 million ...
via Bing News